Enterprise Value
1.892M
Cash
4.145M
Avg Qtr Burn
-5.67M
Short % of Float
10.19%
Insider Ownership
14.30%
Institutional Own.
14.71%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TCR-T targeting neoantigens Details Cancer, Solid tumor/s | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued | |
Ad-RTS-hIL-12 + veledimex (Controlled IL-12) Details Glioblastoma, Cancer | Failed Discontinued |